38 Imported Medical Devices in One Day

1. Executive Summary

On November 8, 2022, during the fifth China International Import Expo (CIIE) in Shanghai, 13 of the city’s municipal-level public hospitals signed a single-day procurement agreement for 38 imported large medical devices worth ¥570 million (roughly US$80 million at prevailing exchange rates). The signing was organized by the Shanghai Shenkang Hospital Development Center, the municipal body that governs Shanghai’s public hospitals, acting as the “Shanghai Trading Group” — a phrase that describes the city’s collective purchasing delegation at the expo. Across the 38 units, the average order value worked out to about ¥15 million (≈US$2.1 million) per device, which tells you immediately that this was not a bulk purchase of consumables or beds. It was a concentrated buy of the most expensive, most regulated equipment a hospital can own: high-field MRI systems, multi-slice CT scanners, PET-CT and PET-MR platforms, angiography suites, radiotherapy linear accelerators, and surgical robotics.

For a foreign medical device manufacturer, this single ceremony is a compressed case study in how China buys advanced capital equipment today. It shows who actually holds the purse strings in a large public hospital system, how procurement is pooled to create negotiating leverage, why imported equipment still commands a premium in categories where domestic alternatives exist, and where the real commercial openings are now that Beijing is simultaneously pushing localization and loosening the permits that gate large-equipment purchases. This article unpacks the deal, the numbers behind it, and the practical playbook it implies for suppliers selling into the world’s second-largest medical device market.

2. The Deal

What was bought

The 38 devices signed on that single day were concentrated in the heaviest, most capital-intensive classes of hospital equipment. While the organizers did not publish a unit-by-unit line sheet, the equipment spans the categories that dominate Shanghai’s “large medical equipment” procurements: magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET-CT), digital subtraction angiography (DSA), linear accelerators for radiation oncology, and, increasingly, robotic surgical systems. These are precisely the products classified in China’s regulatory system as large medical equipment (大型医用设备) — devices whose configuration historically required a national or provincial license before a hospital could even purchase them.

The ¥15 million average masks a wide spread. A high-end 3.0T MRI or a premium 320-slice CT can land in the ¥10–25 million range; a PET-CT or a stereotactic radiotherapy system can run to ¥30–50 million; a single surgical robot installation frequently exceeds ¥20 million. A few flagship systems therefore carry most of the basket’s value, while the balance consists of second- and third-generation imaging replacements.

How the procurement was structured

The important detail for any supplier is not the list price but the buying structure. This was a centralized, pooled purchase. Rather than 13 hospitals negotiating independently, Shenkang aggregated demand across the municipal hospital network and signed a single framework of contracts at the expo. Pooling does two things at once. First, it gives the buyer — effectively the city government acting through its hospital-management arm — enough volume to extract discounts and after-sales commitments that no individual hospital could win. Second, it turns the signing ceremony into a policy signal: Shanghai uses the CIIE stage each year to demonstrate that the “opening-up dividend” of the expo translates directly into better clinical equipment for its residents.

This is not a one-off. Shanghai has repeated the exercise at every CIIE since: across seven editions, its municipal hospitals have collectively signed for close to 200 large medical devices, with the 2023 edition seeing 16 hospitals sign for 32 imported large devices and the 2024 edition following with another centralized batch. The 2022 deal is the largest and cleanest illustration of the mechanism — 38 units, 13 hospitals, ¥570 million, one day.

Why it happened at the CIIE

The timing matters commercially. The CIIE is Beijing’s flagship import event, and it gives the procurement a political umbrella that smooths a process which is otherwise slow and permission-laden. Buying a large medical device in China is not like buying a server. Historically, hospitals needed a configuration permit (配置证) — a quota issued by the National Health Commission for Class A equipment or by provincial authorities for Class B — before procurement could even begin. Signing inside the expo framework lets hospitals demonstrate that demand is pre-approved, financing is ready, and the transaction advances national policy. For the foreign vendor, the same umbrella shortens what is otherwise an 18–36 month cycle from clinical justification to installation.

3. The Numbers That Matter

The single-day deal is best read against the wider trade numbers, because they reveal a market that is enormous, still import-heavy at the top end, and simultaneously tilting toward domestic supply.

The import picture

China is the world’s second-largest medical device market, accounting for roughly a quarter of global consumption, second only to the United States at about 31%. Medical device imports remain a large, if now-declining, flow. According to industry trade data, China’s total medical device imports came in at about US$47.99 billion in 2025, down 2.27% year on year — a decline that has persisted as domestic substitution advances. On the export side, the same dataset shows China’s medical device exports reaching roughly US$52.37 billion in 2025, the third consecutive year of recovery. China has, in other words, already become a net exporter in aggregate medical devices — but that aggregate conceals a sharp, durable asymmetry: the high-end, high-value capital equipment that hospitals like Shanghai’s 13 are still buying is overwhelmingly imported, while China’s exports remain weighted toward consumables, low- and mid-range devices, and components.

The size of the domestic equipment market

The domestic market behind the deal is measured in the trillions of yuan. China’s medical equipment market reached approximately ¥1.35 trillion (about US$188 billion) in 2024, and medical imaging equipment alone — the core of this deal — was estimated at roughly ¥180 billion (about US$25 billion) for that year. Within imaging, ultrasound is the largest single segment and CT/MRI combined account for roughly a third of the category. These are not niches; they are the backbone of a hospital modernization wave that the state has explicitly financed through successive “large equipment update” and county-hospital upgrading programs.

What the unit economics imply

Divide ¥570 million by 38 devices and you get ¥15 million per unit. For a supplier, that arithmetic matters because it defines the customer segment. These buyers are not price-shopping small private clinics; they are top-tier, state-financed, tertiary teaching hospitals where the decision is driven by clinical capability, throughput, and total cost of ownership over a 10–15 year asset life. The willingness to commit ¥570 million in one afternoon also demonstrates that budget is not the binding constraint for this tier of customer — the binding constraints are regulatory approval, clinical evidence, and a local service and training footprint that can justify the premium.

4. Why Hospitals Buy Imported

To a foreign manufacturer, the most important question is not “how big is the market” but “why does an imported device still win when domestic competitors exist?” The answer has four layers, and each one is actionable.

1. The localization gap persists at the top of the stack

China’s domestic substitution campaign has been real and measurable, but it is uneven. High-end medical imaging localization — measured as the domestic share of high-end imaging devices — rose from about 25% to roughly 42% over a six-year window, and the state now claims basic “self-controllability” in high-end medical equipment. Yet the same data contains the caveat that matters most to foreign suppliers: the substitution is deepest in mid-range ultrasound, mid-tier CT, and general radiography, while the clinical and technical frontier — ultra-high-field MRI, spectral and photon-counting CT, integrated PET-MR, and the most advanced radiotherapy and robotics platforms — remains a segment where imported systems are still preferred for their clinical maturity, image quality, workflow software, and installed-base evidence. A hospital buying a flagship 3.0T MRI or a high-end linear accelerator is often buying a reference machine that anchors the department’s reputation, and in that role the imported brand still carries weight.

2. Trust is a clinical and legal asset

For the doctors who actually sign off on the specification, a device is a liability as much as an asset. Radiologists, oncologists, and surgeons face the downstream consequences of a mis-specified machine every day, and hospital leadership faces accountability if a ¥20 million acquisition underperforms. Imported equipment carries decades of peer-reviewed clinical evidence, global reference sites, and a track record across the same Shanghai teaching hospitals that are now buying again. That accumulated trust is not marketing; it is the rational behavior of a buyer whose personal and institutional risk is concentrated in a single high-value decision. Domestic brands have narrowed this gap, but in the flagship category, the burden of proof still falls on the newcomer.

3. Procurement is being upgraded, not just replaced

A common misreading is that China is buying imported equipment because it has no choice. The more accurate reading is that hospital procurement is being upgraded — from aging fleets and first-generation domestic systems toward the best available technology for increasingly complex caseloads. Shanghai’s tertiary hospitals treat the most difficult patients in the country, and their equipment refresh cycles are driven by the need for higher throughput, lower dose, faster scans, and AI-assisted reading. When the upgrade target is defined in those terms, the shortlist is often global by definition. The ¥570 million order is, in effect, a signal that Shanghai’s hospitals are moving up the technology ladder, and the vendors who can climb with them — foreign or domestic — get the order.

4. Policy cuts both ways

Beijing’s localization push is real, but so is its relaxation of the barriers that kept large-equipment purchases slow. The 2023 revision of the national large-medical-equipment configuration permit catalog cut the managed list from 10 categories to 6, reduced Class A (centrally approved) items from 4 to 2 and Class B (provincially approved) items from 6 to 4, and — critically — removed the permit requirement for common 64-slice-and-above CT and 1.5T-and-above MRI, while a related procurement rule gave hospitals full autonomy over equipment purchases below ¥30 million. The net effect is to expand the addressable market for high-end equipment at the same time that domestic firms are scaling up. Both dynamics raise the stakes for foreign suppliers: more machines will be bought, but each will be contested harder.

5. The Market Behind It

The ¥570 million deal is a single day’s expression of a structural, multi-year investment cycle. Understanding that cycle is what separates suppliers who win a one-off order from those who build a position.

A modernization wave with state financing

China’s hospital equipment market is not left to market forces alone. The state has run successive rounds of explicit equipment-upgrade policy — the most recent being a nationwide “large-scale equipment renewal” push — together with county-level hospital upgrading, national and regional medical center construction, and the expansion of diagnosis and treatment capacity in tertiary hospitals. These programs effectively underwrite the demand that Shanghai’s pooled purchases represent. For a supplier, the practical consequence is that demand is concentrated, financed, and timed by policy windows rather than spread evenly across the year.

The geography of demand

Shanghai is the tip of the iceberg, not the whole market. The same pooled-procurement mechanism operates in other major cities and provincial capitals, and the highest growth in large-equipment demand is increasingly in second- and third-tier cities and county-level institutions that are being pushed to upgrade. A supplier who wins in Shanghai’s flagship hospitals earns a reference that travels: provincial buyers routinely copy the equipment decisions of top Shanghai institutions, which is why the expo deal has outsized strategic value beyond its ¥570 million face amount.

The installed-base opportunity

Because Chinese hospitals have been buying imported imaging and radiotherapy equipment for two decades, the installed base is now large enough that service, upgrades, and replacement cycles are a market in their own right. A meaningful share of every pooled purchase is replacement of older imported systems, and the vendor holding the service relationship has a structural advantage when the replacement tender opens.

6. The Competitive Context

The competitive landscape for large medical equipment in China has shifted decisively, and any realistic strategy must account for it.

The domestic challengers are real

United Imaging, Mindray, Neusoft Medical, and a cluster of radiotherapy and robotics firms have moved from being low-cost alternatives to credible mid- and high-end competitors. Their rise is reflected in the localization-rate data and in an export story that now pushes Chinese systems into emerging markets. In mid-tier imaging, they increasingly win on price and on integration with domestic hospital IT ecosystems. The result is that the “imported” share of the market is being contested from below, and the contest is migrating up-market as domestic systems accumulate installed references.

Where the foreign advantage concentrates

The foreign position is now concentrated in the clinical frontier rather than the broad middle: ultra-high-field MRI, spectral/photon-counting CT, integrated PET-MR, high-end angiography, advanced radiotherapy platforms, and premium surgical robotics. These are the categories where Shanghai’s pooled purchases still land overwhelmingly on imported systems, and where the clinical-evidence and workflow-software moats are deepest. The strategic implication is blunt: foreign suppliers cannot win a cost race against domestic incumbents in the middle of the market, and should not try. The winning position is to be the technology frontier that domestic buyers still benchmark against.

The policy overlay

Localization pressure is real but targeted. Beijing’s procurement guidance increasingly favors domestic products where equivalent domestic products exist — a phrase that does much of the practical work, because “equivalent” is judged category by category and, at the frontier, is often not yet satisfied. Suppliers who can demonstrate genuine, non-substitutable clinical capability continue to find purchase approval and budget available. The suppliers who are squeezed are those selling mid-tier technology at frontier prices, a position that is now defensible almost nowhere.

7. The Opportunity for Foreign Suppliers

The deal is best read not as a curiosity but as a template. Here is the playbook it implies.

1. Sell into the pooled-procurement channel, not around it

Shanghai’s model — Shenkang aggregating demand across its hospital network and signing at the CIIE — is the highest-leverage channel in the market. Foreign suppliers should build a dedicated key-account structure for hospital-management bodies and provincial trading groups, not a patchwork of hospital-by-hospital sales. Winning one framework agreement with Shenkang-class buyers unlocks a fleet of institutions at once and converts a political event into a commercial one. Align product launches and pricing announcements with the CIIE cycle, where the signing stage itself has commercial value.

2. Anchor on the clinical frontier, not the commodity middle

The durable foreign position is where domestic equivalence has not yet been achieved. Concentrate R&D, regulatory, and go-to-market investment on ultra-high-field MRI, spectral and photon-counting CT, integrated PET-MR, high-end DSA, adaptive radiotherapy, and premium robotics. In these categories, the purchase is a reference decision, and Shanghai’s flagship hospitals are exactly the reference sites that set the standard for the rest of the country.

3. Win the total-cost-of-ownership and evidence argument

At ¥15 million per device, buyers are optimizing a 10–15 year clinical and financial commitment, not sticker price. Foreign suppliers should lead with total cost of ownership, uptime guarantees, service response commitments, upgrade roadmaps, and — above all — peer-reviewed clinical evidence and named Chinese reference sites. Losers typically lose on perceived risk and serviceability, not list price.

4. Localize the parts that de-risk the sale

Localization does not mean giving away the frontier. A local service organization, a spare-parts and applications-training hub, Chinese-language AI and workflow software, and co-developed clinical packages all reduce perceived risk without surrendering the technology. In practice, the imported systems that win in Shanghai are those backed by substantial in-country presence.

5. Ride the policy tailwinds, but time them

The 2023 permit-catalog relaxation and the equipment-renewal programs are expanding the market precisely at the high end. Suppliers should map national and provincial policy windows — configuration permits, renewal funding cycles, medical-center construction plans — and align sales and financing offers to them. Deals close when a hospital holds both the permit and the budget; the vendors present at that moment, with financing and installation slots ready, capture the order.

6. Treat Shanghai as a national reference asset

A ¥570 million, 13-hospital signing in Shanghai propagates across the country: provincial and prefecture-level buyers replicate the equipment choices of top Shanghai institutions. Every flagship installation should be documented as a reference for lower-tier buyers and leveraged into the second- and third-tier renewal wave now driving market growth.

8. Conclusion

Thirty-eight imported large medical devices, thirteen hospitals, ¥570 million, one day: the Shanghai deal of November 2022 compresses the entire structure of China’s high-end medical equipment market into a single signing ceremony. It shows a buyer that is centralized, state-financed, policy-driven, and still willing to pay a premium for imported technology at the clinical frontier — even as domestic competitors close the gap below it.

For foreign suppliers, the lesson is not that China’s market is open or closed. It is that the market has stratified. The broad middle is being conceded to domestic firms and to price competition; the frontier, where a ¥15 million machine is a clinical and reputational decision rather than a cost decision, remains open to vendors who can prove non-substitutable capability, back it with evidence and a local footprint, and sell through the pooled-procurement channels that cities like Shanghai have built. The winners in the next decade will be those who treat deals like this one not as anomalies, but as the blueprint for how China buys.